Eric Ruderman
- Rheumatology top 0.5%
- Rheumatoid Arthritis Research and Therapies 55
- Spondyloarthritis Studies and Treatments 24
- Systemic Lupus Erythematosus Research 21
- Hematology top 1%
- Autoimmune and Inflammatory Disorders Research 19
- Immunology top 2%
- Psoriasis: Treatment and Pathogenesis 15
- Biosimilars and Bioanalytical Methods 4
- Dermatology top 2%
-
- Monoclonal and Polyclonal Antibodies Research 5
-
- Chronic Lymphocytic Leukemia Research 4
- Co-authors
- Christopher T. RitchlinErnest ChoyRenee PerdokPhilip J. MeaseDafna D. GladmanJohn T. SharpP A OrySerge Steinfeld
- Cited by
- RheumatologyHematologyImmunology
- Journals
- The Journal of Rheumatology (5 papers)Annals of the Rheumatic Diseases (5 papers)Lara D. Veeken (4 papers)
- Partner nations
- United StatesAustraliaGermany
In The Last Decade
Eric Ruderman
81 papers receiving 2.8k citations
Hit Papers
Peers
Comparison fields: 5 of 120
- Rheumatology 1.6k
- Hematology 773
- Immunology 1.2k
- Pathology and Forensic Medicine 476
- Dermatology 221
Countries citing papers authored by Eric Ruderman
This map shows the geographic impact of Eric Ruderman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Ruderman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Ruderman more than expected).
Fields of papers citing papers by Eric Ruderman
This network shows the impact of papers produced by Eric Ruderman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Ruderman. The network helps show where Eric Ruderman may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Eric Ruderman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 5 | |
| 2 | 2021 | 17 | |
| 3 | 2021 | 31 | |
| 4 | Understanding vaccination rates and attitudes among patients with rheumatoid arthritis. | 2016 | 19 |
| 5 | IL-6 inhibition for the treatment of rheumatoid arthritis and other conditions. | 2012 | 11 |
| 6 | Interleukin 6 inhibition - RA and beyond. | 2011 | 12 |
| 7 | Th17 cells expressing KIR3DL2 + and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis: Commentary | 2011 | 2 |
| 8 | Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation: Commentary | 2011 | 1 |
| 9 | Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS): Commentary | 2011 | 1 |
| 10 | Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients: Commentary | 2011 | 1 |
| 11 | No overall progression and occasional repair of erosions despite persistent inflammation in adalimumab-treated rheumatoid arthritis patients: Results from a longitudinal comparative MRI, ultrasonography, CT and radiography study - Commentary | 2011 | 1 |
| 12 | Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): A 48- week randomised controlled trial - Commentary | 2011 | 0 |
| 13 | Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome: Commentary | 2011 | 1 |
| 14 | Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway: Commentary | 2011 | 2 |
| 15 | Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis: Commentary | 2011 | 1 |
| 16 | Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: Exploratory analyses from the BeSt study - Commentary | 2011 | 1 |
| 17 | Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: Results of the ESTHER trial at week 48 - Commentary | 2011 | 0 |
| 18 | The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study: Commentary | 2011 | 1 |
| 19 | Anti-interleukin-6 therapy in rheumatoid arthritis. | 2010 | 26 |
| 20 | 24-Week efficacy and safety results from the adalimumab effectiveness in psoriatic arthritis trial (ADEPT) | 2005 | 0 |
About Eric Ruderman
Eric Ruderman is a scholar working on Rheumatology, Hematology and Immunology, having authored 84 papers that have together received 2.9k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (55 papers), Spondyloarthritis Studies and Treatments (24 papers), Systemic Lupus Erythematosus Research (21 papers), Autoimmune and Inflammatory Disorders Research (19 papers), Psoriasis: Treatment and Pathogenesis (15 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Biosimilars and Bioanalytical Methods (4 papers). The work is most often cited by research in Rheumatology (1.6k citations), Hematology (773 citations) and Immunology (1.2k citations). Eric Ruderman has collaborated with scholars based in United States, Australia and Germany. Frequent co-authors include Christopher T. Ritchlin, Ernest Choy, Renee Perdok, Philip J. Mease, Dafna D. Gladman, John T. Sharp, P A Ory, Serge Steinfeld, Mark Weinberg and Richard M. Pope. Their work appears in journals such as The Journal of Rheumatology, Annals of the Rheumatic Diseases, Lara D. Veeken, Rheumatology and Therapy and Arthritis Care & Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.